Single Boron Coordination on a Strong [1,2,5]Thiadiazolo[3,4-g]Quinoxaline Acceptor Enables Intense NIR-II Absorption for Photoacoustic Imaging-Guided Photothermal Therapy
Qing-Yun Ni , Zhaobo Liu , Zhaohui Dai , Yu Dong , Wenli Li , Ya Li , Haiming Zhu , Meng Li , Kang Yuan , Bing Wang
Aggregate ›› 2026, Vol. 7 ›› Issue (7) : e70407
Strong near-infrared-II (NIR-II, 1000–1700 nm) absorbers with high photothermal efficiency are highly desirable for deep-tissue photoacoustic imaging and photothermal therapy. However, donor–acceptor (D–A) molecular design strategies that simultaneously achieve structural robustness and intense NIR-II absorption remain scarce. Herein, we demonstrate that single-boron coordination can be implemented on the intrinsically strong acceptor [1,2,5]thiadiazolo[3,4-g]quinoxaline (TQ), an unachieved regime by previously reported boron-engineered strategies, which have typically been based on weaker electron-deficient acceptors. Single intramolecular N→B–N coordination converts TQ into an even stronger electron-deficient motif than the widely used benzobis(thiadiazole) (BBT) acceptor. Through donor engineering and planarity modulation, the resulting borylated TQ derivative, BLD3, exhibits intense NIR-II absorption with a high molar extinction coefficient (ε > 3 × 104 M−1 cm−1) around 1000 nm in toluene. Featuring an ultrafast nonradiative decay of 2.1 ps, BLD3 nanoparticles (NPs) show a high photothermal conversion efficiency of 68% under 1060 nm laser irradiation, as well as a robust photoacoustic (PA) output under 1064 nm excitation. Combining excellent photo/thermal stability, favorable tumor accumulation, and good biocompatibility, BLD3 NPs enable effective NIR-II PA imaging-guided photothermal therapy with pronounced tumor ablation. This work expands the library of strong acceptors for boron-coordination chemistry, providing a general platform for constructing powerful electron-deficient building blocks and high-performance NIR-II phototheranostic materials.
acceptor engineering / boron coordination / NIR-II absorption / photothermal therapy
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
2026 The Author(s). Aggregate published by SCUT, AIEI, and John Wiley & Sons Australia, Ltd.
/
| 〈 |
|
〉 |